bioAffinity
  • Home
  • Publications
  • News
  • About Us
  • Videos
  • Contact
  • Investor Relations
Select Page

bioAffinity Technologies Announces Formation of Scientific and Medical Advisory Board; M. Patricia Rivera, MD, Joins Board as Chair

by Maria Zannes | Mar 12, 2019 | Press Releases

MARCH 12, 2019 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, today announced the formation of a Scientific and Medical Advisory (SMA) Board to provide independent expert advice and counsel on the Company’s research and development of...

bioAffinity Technologies Selected as Finalist for Cancer Innovation Award

by Maria Zannes | Mar 6, 2019 | Press Releases

MARCH 6, 2019 (San Antonio, TX) Healthcare innovators Lyfebulb and Helsinn selected bioAffinity Technologies, a privately held biotech company developing diagnostics and therapeutics for cancer, as one of 10 finalists for the second annual in Oncology. The Innovation...

bioAffinity named a finalist in the Lyfebulb Helsinn 2019 Innovation Summit in Oncology

by Maria Zannes | Mar 6, 2019 | News

BioAffinity Technologies is proud to be named a finalist in the Lyfebulb Helsinn 2019 Innovation Summit in Oncology. Lyfebulb-Helsinn Innovation Summit March 18 and 19, 2019 Monaco,  Principality of Monaco Ten finalists will compete at the second annual...

bioAffinity Technologies Announces Award of Canadian Patent

by Maria Zannes | Feb 5, 2019 | Press Releases

FEBRUARY 4, 2019 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, announced that the Canadian Intellectual Property Office has awarded a patent expanding the Company’s claims associated with its proprietary CyPath© technology for the early...
Next Entries »

Categories

  • Articles (18)
  • Events (38)
  • News (43)
  • Press Releases (70)
  • Publications (16)

Recent Posts

  • bioAffinity Technologies Acquires Laboratory Assets of Precision Pathology Services September 19, 2023
  • bioAffinity Technologies to Participate in the H.C. Wainwright Global Investment Conference September 7, 2023
  • bioAffinity Technologies Reports Second Quarter 2023 Financial Results and Provides Business Update August 10, 2023
  • AMA Issues CPT Code for bioAffinity Technologies’ CyPath® Lung Test for Early-Stage Lung Cancer July 12, 2023
  • bioAffinity Technologies Presents Research Findings at UMass RNA Therapeutics Symposium June 15, 2023

Learn About CyPath Lung

CyPath Lung Test

Main Menu

  • Home
  • Publications
  • News
  • About Us
  • Videos
  • Contact
  • Investor Relations
Copyright © 2023 bioAffinity Technologies, Inc.